Published in Cancer Res on November 15, 2007
Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle (2010) 2.67
FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer (2014) 2.46
A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem (2008) 2.31
Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev (2010) 2.21
PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther (2010) 2.10
A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle (2009) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
Role of kinase-independent and -dependent functions of FAK in endothelial cell survival and barrier function during embryonic development. J Cell Biol (2010) 1.44
Inhibition of podocyte FAK protects against proteinuria and foot process effacement. J Am Soc Nephrol (2010) 1.44
FERM control of FAK function: implications for cancer therapy. Cell Cycle (2008) 1.43
Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther (2010) 1.41
RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res (2008) 1.27
The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther (2010) 1.22
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis (2012) 1.20
Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med Chem (2010) 1.19
Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res (2010) 1.17
HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res (2010) 1.16
Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One (2008) 1.11
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem (2011) 1.09
Focal adhesion kinase and endothelial cell apoptosis. Microvasc Res (2011) 1.05
FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin Exp Metastasis (2012) 1.05
Targeting Pyk2 for therapeutic intervention. Expert Opin Ther Targets (2010) 1.04
Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol Carcinog (2010) 1.01
Changes in gene expression and cellular architecture in an ovarian cancer progression model. PLoS One (2011) 1.01
Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci (Landmark Ed) (2014) 0.99
β1 integrin: an emerging player in the modulation of tumorigenesis and response to therapy. Cell Adh Migr (2012) 0.94
FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther (2014) 0.91
Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy. Cancer Biol Ther (2013) 0.89
Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol (2010) 0.89
Enterolobium contortisiliquum trypsin inhibitor (EcTI), a plant proteinase inhibitor, decreases in vitro cell adhesion and invasion by inhibition of Src protein-focal adhesion kinase (FAK) signaling pathways. J Biol Chem (2011) 0.89
TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis. Invest New Drugs (2009) 0.88
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther (2014) 0.87
Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res (2012) 0.85
FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells. PLoS One (2011) 0.85
Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Mol Cancer (2014) 0.84
Progress in researches about focal adhesion kinase in gastrointestinal tract. World J Gastroenterol (2009) 0.84
A non-canonical role for Rgnef in promoting integrin-stimulated focal adhesion kinase activation. J Cell Sci (2013) 0.82
Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to cisplatin. BMB Rep (2015) 0.81
Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.). J Mol Cell Cardiol (2013) 0.81
Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol (2014) 0.81
Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities. Anticancer Agents Med Chem (2013) 0.81
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des (2012) 0.81
PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther (2015) 0.80
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium. Mol Cancer (2014) 0.80
Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment. Clin Cancer Res (2016) 0.79
Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. J Histochem Cytochem (2014) 0.79
Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clin Exp Metastasis (2015) 0.78
Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival. J Surg Res (2015) 0.78
RhoGEFs in cell motility: novel links between Rgnef and focal adhesion kinase. Curr Mol Med (2014) 0.78
Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain. J Transl Med (2013) 0.78
FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget (2016) 0.78
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. Oncogenesis (2017) 0.78
Invasion of epithelial cells by Campylobacter jejuni is independent of caveolae. Cell Commun Signal (2013) 0.77
Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight (2016) 0.76
A simple knowledge-based mining method for exploring hidden key molecules in a human biomolecular network. BMC Syst Biol (2012) 0.75
The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer. Mol Pharmacol (2016) 0.75
Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer. Cancer Lett (2014) 0.75
Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells. Exp Cell Res (2014) 0.75
Targeting focal adhesion kinase in neuroblastoma. Anticancer Agents Med Chem (2010) 0.75
Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets. Front Endocrinol (Lausanne) (2012) 0.75
TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. PLoS One (2015) 0.75
Prognostic biomarkers in ovarian cancer. Cancer Biomark (2011) 0.75
PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells. J Mol Neurosci (2012) 0.75
PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment. Autophagy (2017) 0.75
Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions. Technol Cancer Res Treat (2016) 0.75
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS One (2017) 0.75
Integrin Activation Contributes to Lower Cisplatin Sensitivity in MV3 Melanoma Cells by Inducing the Wnt Signalling Pathway. Cancers (Basel) (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res (2006) 3.58
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging (2004) 3.07
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med (2004) 2.89
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2009) 2.80
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy (2010) 2.62
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med (2005) 2.43
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Characterization of CD45-/CD31+/CD105+ circulating cells in the peripheral blood of patients with gynecologic malignancies. Clin Cancer Res (2013) 2.07
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther (2007) 1.97
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88